FrancophonIA/ELRC3.0 huggingface dataset:
English: The main route of hepatic transformation of binimetinib being glucoronidation, the decision for treatement should be made by the treating physician taking into account the individual benefit-risk.
Croatian: Budući da je glavni put jetrene transformacije binimetiniba glukoronidacija, odluku o liječenju mora donijeti liječnik koji provodi liječenje, uzimajući u obzir individualni omjer rizika i koristi.
English: Mektovi targets another protein called “MEK” that stimulates cancer cell growth.
Croatian: Lijek Mektovi cilja drugi protein pod nazivom „MEK” koji pospješuje rast stanica raka.
English: See section 2 “Mektovi contains lactose”.
Croatian: Vidjeti dio 2. „Lijek Mektovi sadrži laktozu”.
English: If binimetinib is used during pregnancy, or if the patient becomes pregnant while taking binimetinib, the patient should be informed of the potential hazard to the foetus.
Croatian: Ako se binimetinib primjenjuje tijekom trudnoće ili bolesnica zatrudni tijekom liječenja binimetinibom, bolesnicu je potrebno informirati o mogućem riziku za plod.
English: Suspicious skin lesions should be managed with dermatological excision and dermatopathologic evaluation.
Croatian: Svaku se sumnjivu kožnu leziju mora kirurški odstraniti i poslati na dermatopatološku analizu.
English: In vitro experiments indicate that binimetinib is a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP).
Croatian: Na temelju in vitro ispitivanja utvrđeno je da je binimetinib supstrat P-glikoproteina (P-gp) i proteina rezistencije raka dojke na lijekove (BCRP).
English: The safety of binimetinib has not been established in patients with predisposing factors for RVO including uncontrolled glaucoma, ocular hypertension, uncontrolled diabetes mellitus or a history of hyperviscosity or hypercoagulability syndromes.
Croatian: Sigurnost binimetiniba nije ustanovljena u bolesnika s predispozicijskim čimbenicima RVO-a, uključujući nekontrolirani glaukom, očnu hipertenziju, nekontroliranu šećernu bolest ili sa sindromom hiperviskoznosti ili hiperkoagulabilnosti u anamnezi.
English: It should be ensured that patient has adequate hydration.
Croatian: Treba osigurati adekvatnu hidraciju bolesnika.
English: Administration of a single 45 mg dose of binimetinib with a high-fat, high-calorie meal decreased the maximum binimetinib concentration (Cmax) by 17 %, while the area under the concentration-time curve (AUC) was unchanged.
Croatian: Primjena jedne doze od 45 mg binimetiniba uz obrok s velikim udjelom masti, visokokalorični obrok, snižava maksimalnu koncentraciju binimetiniba (Cmax) za 17%, dok površina ispod krivulje koncentracija - vrijeme (AUC) ostaje nepromijenjena.
English: Special attention should be paid to patients with neuromuscular conditions associated with CK elevation and rhabdomyolysis.
Croatian: Posebna se pažnja mora obratiti na bolesnike sa živčanomišićnim poremećajima povezanim s povišenjem kreatin kinaze i rabdomiolizom.
English: Binimetinib dose should be maintained and it should be ensured that patient is adequately hydrated.
Croatian: Treba održavati dozu binimetiniba i osigurati adekvatnu hidraciju bolesnika.
English: A drug interaction study in healthy subjects indicated that the extent of binimetinib exposure is not altered in the presence of a gastric pH-altering agent (rabeprazole).
Croatian: Istraživanje interakcije lijekova u zdravih ispitanika ukazuje na to da opseg izloženosti binimetinibu nije promijenjen u prisustvu lijeka koji mijenja želučani pH (rabeprazol).
English: The highest dose of binimetinib evaluated as single agent in clinical studies was 80 mg administered orally twice daily and was associated with ocular (chorioretinopathy) and skin toxicities (dermatitis acneiform).
Croatian: Najviša doza binimetiniba procijenjenog kao samostalni lijek u kliničkim ispitivanjima bila je 80 mg, primijenjena peroralno dvaput dnevno te se povezuje s očnom (korioretinopatija) i kožnom toksičnošću (akneiformni dermatitis).
English: Patients receiving Combo 450 reported no change or a slight improvement in the mean change from baseline EQ-5D-5L index score at all visits, whilst patients receiving vemurafenib or encorafenib reported decreases at all visits (with statistical significant differences).
Croatian: Bolesnici koji su primali kombiniranu terapiju 450 nisu prijavili nikakve promjene ili su prijavili blago poboljšanje prosječne promjene u odnosu na početnu vrijednost prema rezultatu EQ-5D-5L indeksa u svim posjetima, dok su bolesnici koji su liječeni vemurafenibom ili enkorafenibom prijavili smanjenje pri svim posjetima (sa statistički značajnim razlikama).
English: It is not known if Mektovi passes into breast milk.
Croatian: Nije poznato prelazi li Mektovi u majčino mlijeko.
English: Tell your doctor if you have ever had blockage in the vein carrying blood away from the eye (retinal vein occlusion), as Mektovi is not recommended in such cases.
Croatian: • probleme s jetrom Obavijestite svog liječnika ako ste ikad imali začepljenje vene koja odvodi krv iz oka (okluzija mrežnične vene), jer se lijek Mektovi ne preporučuje u takvom slučaju.
English: There are no data from the use of binimetinb in pregnant women.
Croatian: Nema podataka o primjeni binimetiniba u trudnica.
English: Most events were reported as retinopathy, retinal detachment, subretinal fluid, macular oedema, and chorioretinopathy and led to dose interruptions or dose modifications in 4.7 % (13/274) of patients.
Croatian: Većina događaja prijavljena je kao retinopatija, odvajanje mrežnice, subretinalna tekućina, makularni edem i korioretinopatija te je dovela do prekida primjene doze ili izmjene doze u 4,7% (13/274) bolesnika.
English: Yellow to dark yellow, unscored biconvex, ovaloid film-coated tablets approximately 12 mm in length and 5 mm in width, with the “A” logo debossed on one side of the tablet and “15” on the other side.
Croatian: Žuta do tamno žuta, bez ureza, bikonveksna, ovalna filmom obložena tableta dužine približno 12 mm i širine približno 5 mm, s oznakom „A” utisnutom s jedne strane tablete i „15” s druge strane.
English: Do not use this medicine after the expiry date which is stated on the blister and the carton after EXP.
Croatian: Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na blisteru i kutiji iza oznake Rok valjanosti ili EXP.
English: New onset elevated blood pressure or worsening of pre-existing hypertension were reported in 11.7 % (32/274) of patients treated with the Combo 450.
Croatian: Nova pojava povišenog krvnog tlaka ili pogoršanje postojeće hipertenzije prijavljeni su u 11,7% (32/274) bolesnika liječenih kombiniranom terapijom 450.
English: Encorafenib + binimetinib n = 192 (Combo 450)
Croatian: Enkorafenib + binimetinib n = 192 (kombinirana terapija 450)
English: As binimetinib is primarily metabolised and eliminated via the liver, patients with moderate to severe hepatic impairment may have increased exposure.
Croatian: Kako se binimetinib primarno metabolizira i eliminira putem jetre, u bolesnika s umjerenim do teškim oštećenjem jetrene funkcije izloženost lijeku može biti povećana.
English: Rhabdomyolysis was reported in 0.4 % (1/274) of patients treated with encorafenib in combination with binimetinib.
Croatian: Rabdomioliza je prijavljena u 0,4% (1/274) bolesnika liječenih enkorafenibom u kombinaciji s binimetinibom.
English: Other side effects when Mektovi and encorafenib are taken together:
Croatian: Druge nuspojave pri istodobnoj primjeni lijekova Mektovi i enkorafeniba:
English: The median duration of exposure was 11.7 months in patients treated with Combo 450, 7.1 months in patients treated with encorafenib 300 mg and 6.2 months in patients treated with vemurafenib.
Croatian: Medijan duljine liječenja bio je 11,7 mjeseci u skupine liječene kombiniranom terapijom 450, 7,1 mjesec u skupine liječene enkorafenibom 300 mg i 6,2 mjeseca u skupine liječene vemurafenibom.
English: Results from a dedicated clinical study with binimetinib only indicate similar exposures in patients with mild impairment (Child-Pugh Class A) and subjects with normal liver function.
Croatian: Rezultati iz posebnog kliničkog ispitivanja samo bimetiniba ukazuju na sličnu izloženost u bolesnika s blagim oštećenjem jetrene funkcije (Child-Pugh A) i ispitanika s normalnom jetrenom funkcijom.
English: Vemurafenib n = 191 (Vem)
Croatian: Vemurafenib n = 191 (vemurafenib)
English: • high blood pressure
Croatian: • visok krvni tlak • krvne ugruške
English: The effects of renal impairment on the pharmacokinetics of binimetinib in combination with encorafenib have not been evaluated clinically.
Croatian: Učinci oštećenja funkcije bubrega na farmakokinetiku binimetiniba u kombinaciji s enkorafenibom nisu klinički procijenjeni.
English: Mektovi is an anti-cancer medicine that contains the active substance binimetinib.
Croatian: Lijek Mektovi je lijek protiv raka koji sadrži djelatnu tvar binimetinib.
English: Mektovi is not recommended during pregnancy.
Croatian: Lijek Mektovi ne preporučuje se tijekom trudnoće.
English: Binimetinib should be permanently discontinued in patients diagnosed with treatment related pneumonitis or ILD.
Croatian: Binimetinib se mora trajno obustaviti u bolesnika s dijagnozom pneumonitisa ili ILD-a povezanog s liječenjem.
English: The mean (CV %) apparent clearance (CL/F) of binimetinib was 28.2 L/h (17.5 %).
Croatian: Srednja vrijednost (CV%) prividnog klirensa (CL/F) binimetiniba bila je 28,2 litara/sat (17,5%).
English: If binimetinib is temporarily interrupted, encorafenib should be reduced to 300 mg once daily during the time of binimetinib dose interruption (see Tables 1 and 2) as encorafenib is not well-tolerated at the dose of 450 mg as a single agent.
Croatian: Ako je binimetinib privremeno prekinut, mora se smanjiti dozu enkorafeniba na 300 mg jedanput dnevno tijekom privremenog prekida doze binimetiniba (vidjeti Tablice 1 i 2) jer se enkorafenib ne podnosi dobro pri dozi od 450 mg kod primjene kao samostalan lijek.
English: The pharmacokinetics of binimetinib were studied in healthy subjects and patients with solid tumours and advanced and unresectable or metastatic cutaneous melanoma.
Croatian: Farmakokinetika binimetiniba bila je ispitivana u zdravih ispitanika i bolesnika sa solidnim tumorima i uznapredovalim i neoperabilnim ili metastatskim kožnim melanomima.
English: Table 4 and Figure 1 summarise the PFS and other efficacy results based on central review of the data by a blinded independent radiology committee.
Croatian: sažeto prikazuju PFS i druge rezultate djelotvornosti na temelju središnje analize podataka procijenjenih od strane zaslijepljenog, neovisnog povjerenstva za radiološku procjenu.
English: The median (range) binimetinib terminal half-life (T1/2) was 8.66 h (8.10 to 13.6 h).
Croatian: Medijan (raspon) terminalnog poluvijeka (T1/2) bio je 8,66 sati (raspon od 8,10 do 13,6 sati).
English: Hypertension events were reported as Grade 3 in 5.5 % (15/274) of patients, including hypertensive crisis (0.4 % (1/274)).
Croatian: Događaji hipertenzije prijavljeni su kao stupanj 3 u 5,5% (15/274) bolesnika, uključujući hipertenzivnu krizu (0,4% (1/274)).
English: Pneumonitis/Interstitial lung disease
Croatian: Pneumonitis/intersticijska plućna bolest
English: • Blood clots: Mektovi can cause blood clots in your arms or legs, and if a clot travels to your lungs it could lead to death.
Croatian: • Krvni ugrušci: lijek Mektovi može prouzročiti krvne ugruške u rukama ili nogama te ako ugrušak dospije u pluća, može dovesti do smrti.
English: The median duration of treatment was longer for Combo 300 vs. Enco 300, 52.1 weeks vs 31.5 weeks.
Croatian: Medijan trajanja liječenja je bio duži za kombiniranu terapiju 300 naspram enkorafeniba 300, 52,1 tjedna naspram 31,5 tjedana.
English: • some medicines to treat bacterial infections such as rifampicin, ciprofloxacin
Croatian: • neki lijekovi za liječenje bakterijskih infekcija, kao što su rifampicin i ciprofloksacin
English: Standard genotixicity studies with binimetinib were negative.
Croatian: Rezultati standardnog ispitivanja genotoksičnosti s binimetinibom bili su negativni.
English: Grade 3-4 LVEF, or absolute decrease of LVEF from baseline of ≥ 10 %, binimetinib should be discontinued and LVEF should be evaluated every 2 weeks until recovery.
Croatian: Za svaku simptomatsku disfunkciju lijevog ventrikula, stupanj 3-4 LVEF-a ili apsolutno smanjenje LVEF-a od početne vrijednosti za ≥ 10%, primjena binimetiniba se mora obustaviti, a LVEF se mora procijeniti svaka 2 tjedna do oporavka.
English: • Grade 2 aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3x - ≤ 5x upper limit of normal (ULN)
Croatian: • Aspartat aminotransferaza (AST) ili alanin aminotransferaza (ALT) > 3x - ≤ 5x gornje granice normale (GGN), nuspojava stupnja 2
English: Talk to your doctor immediately if you have any symptoms of bleeding problems such as coughing up of blood, blood clots, vomit containing blood or that looks like “coffee grounds”, red or black stools that look like tar, passing blood in the urine, stomach (abdominal) pain, unusual vaginal bleeding.
Croatian: Odmah obavijestite svog liječnika ako imate bilo kakve simptome krvarenja, kao što su iskašljavanje krvi, krvni ugrušci, povraćanje koje sadrži krv ili izgleda poput „taloga kave”, crvene ili crne stolice koja izgleda poput katrana, krv u mokraći, bol u trbuhu ili neobična krvarenja iz rodnice.
English: - The active substance is binimetinib.
Croatian: - Djelatna tvar je binimetinib.
English: • Grade 2 Left ventricular ejection fraction (LVEF) decrease or asymptomatic, absolute decrease in LVEF of greater than 10 % from baseline that is below lower limit of normal (LLN)
Croatian: Left Ventricular Ejection Fraction, LVEF) stupnja 2 ili asimptomatsko, apsolutno smanjenje LVEF-a veće od 10% od početne vrijednosti čime je ispod donje granice normale (DGN)
English: No clinicallly significant drug-drug interactions caused by binimetinib on other transporters is expected.
Croatian: Ne očekuju se nikakve klinički značajne interakcije između lijekova prouzročene učinkom binimetiniba na druge transportere.
English: *composite terms which included more than one preferred term a includes keratoacanthoma, squamous cell carcinoma, lip squamous cell carcinoma and squamous cell carcinoma of skin b includes angioedema, drug hypersensitivity, hypersensitivity, hypersensitivity vasculitis and urticaria c includes facial nerve disorder, facial paralysis, facial paresis d includes left ventricular dysfunction, ejection fraction decreased, cardiac failure and ejection fraction abnormal e includes haemorrhage at various sites including cerebral haemorrhage f includes pulmonary embolism, deep vein thrombosis, embolism, thrombophlebitis, thrombophlebitis superficial and thrombosis g includes colitis, colitis ulcerative, enterocolitis and proctitis h includes myalgia, muscular weakness, muscle spasm, muscle injury, myopathy, myositis i includes fluid retention, peripheral oedema, localised oedema
Croatian: *kompozitni pojmovi koji uključuju više od jednog preferiranog pojma a uključuje keratoakantom, planocelularni karcinom, planocelularni karcinom usne i planocelularni karcinom kože b uključujući angioedem, preosjetljivost na lijek, preosjetljivost, alergijski vaskulitis i urtikariju c uključujući poremećaj facijalnog živca, facijalnu paralizu, facijalnu parezu d uključujući i disfunkciju lijeve klijetke, smanjenje ejekcijske frakcije, zatajenje srca i poremećaj ejekcijske frakcije e uključujući i krvarenje u bilo kojem dijelu tijela, uključujući i krvarenje u mozgu f uključujući i plućnu emboliju, trombozu dubokih vena, emboliju, tromboflebitis, površinski tromboflebitis i trombozu g uključujući i kolitis, ulcerozni kolitis, enterokolitis i proktitis h uključujući i mijalgiju, slabost mišića, mišićni spazam, oštećenje mišića, miopatiju, miozitis i uključujući i zadržavanje tekućine, periferni edem, lokalizirani edem
English: Hypertension led to dose interruption or adjustment in 2.9 % of patients.
Croatian: Hipertenzija je dovela do potrebe za prilagodbom doze ili privremenog prekida liječenja u 2,9% bolesnika.
English: Unstratified subgroup analyses demonstrated point estimates in favour of Combo 450, including LDH at baseline, ECOG performance status and AJCC stage.
Croatian: Nestratificirana analiza podskupina pokazala je točkovnu procjenu (point estimates) u korist kombinirane terapije 450, uključujući i početne vrijednosti LDH, ECOG status i stupanj AJCC.
English: Visual disturbances have been reported in patients treated with binimetinib during clinical studies.
Croatian: Poremećaji vida primijećeni su u bolesnika liječenih binimetinibom tijekom kliničkih ispitivanja.
English: Eye problems: Mektovi can cause fluid to leak under the retina in the eye, leading to detachment of different layers in the eye (retinal pigment epithelial detachment) which could lead to:
Croatian: Problemi s očima: lijek Mektovi može prouzročiti propuštanje tekućine ispod mrežnice u oku, što rezultira odvajanjem različitih slojeva u oku (odvajanje pigmentnog epitela mrežnice), što može izazvati:
English: Binimetinib is a potential inducer of CYP1A2, and caution should be taken when it is used with sensitive substrates (such as duloxetine or theophylline).
Croatian: Binimetinib je potencijalni induktor enzima CYP1A2 i potreban je oprez kada se koristi s osjetljivim supstratima (kao što su duloksetin ili teofilin).
English: Rhabdomyolysis/Creatine phosphokinase (CK) elevation
Croatian: Rabdomioliza/Povišenje kreatin fosfokinaze (CPK)
English: Your doctor or nurse will check your blood pressure before and during treatment with Mektovi.
Croatian: Vaš će liječnik ili medicinska sestra provjeriti krvni tlak prije i tijekom liječenja lijekom Mektovi.
English: Women of childbearing potential must use effective contraception during treatment with binimetinib and for at least 1 month following the last dose.
Croatian: Žene u reproduktivnoj dobi moraju koristiti učinkovitu kontracepciju tijekom liječenja binimetinibom te najmanje 1 mjesec nakon uzimanja posljednje doze lijeka.
English: Binimetinib is not recommended during pregnancy and in women of childbearing potential not using contraception.
Croatian: Binimetinib se ne preporučuje u trudnica i u žena reproduktivne dobi koje ne koriste kontraceptivnu zaštitu.
English: Contact your doctor straightaway if you become pregnant while taking Mektovi.
Croatian: Odmah se obratite svom liječniku ako zatrudnite dok uzimate lijek Mektovi.
English: Repeated oral administration of binimetinib in rats for up to 6 months was associated with soft tissue mineralisation, gastric mucosal lesions and reversible minimal to mild clinical pathology changes at 7 to 12.5 times human therapeutic exposures.
Croatian: Ponovljena peroralna primjena binimetiniba kod štakora do 6 mjeseci povezuje se s mineralizacijom mekog tkiva, lezijama želučane sluznice i reverzibilnim minimalnim do umjerenim kliničkim patološkim promjenama pri 7 do 12,5 puta većoj izloženosti od one u ljudi pri terapijskim dozama.
English: The median time to onset of the first event was 2.7 months (range: 0.5 to 17.5 months).
Croatian: Medijan vremena do prvog pojavljivanja iznosio je 2,7 mjeseci (u rasponu: od 0,5 do 17,5 mjeseci).
English: In a gastric irritation study in rats, an increased incidence of superficial mucosal lesions and of hemorrhagic ulcers were observed.
Croatian: ispitivanju iritacije želuca kod štakora primijećena je povećana incidencija površinskih lezija sluznice i hemoragičnih ulkusa.
English: CK and creatinine levels should be monitored monthly during the first 6 months of treatment and as clinically indicated.
Croatian: Razine kreatin kinaze i kreatinina se moraju pratiti jedanput mjesečno tijekom prvih 6 mjeseci liječenja i kako je klinički indicirano.
English: Binimetinib and encorafenib should be continued without any dose modifications.
Croatian: S primjenom binimetiniba i enkorafeniba potrebno je nastaviti bez dodatne prilagodbe doze lijeka.
English: Effect of CYP enzymes on binimetinib
Croatian: Učinak CYP enzima na binimetinib
English: Fertility studies were not conducted with binimetinib.
Croatian: Ispitivanja plodnosti nisu provedena s binimetinibom.
English: The mean (CV %) Cmax,ss was 654 ng/mL (34.7 %) and mean AUCss was 2.35 ug.h/mL (28.0 %) in combination with encorafenib as estimated by population PK modelling.
Croatian: Srednja vrijednost (CV%) Cmaks. ss bila je 654 ng/mL (34,7%), ai srednja vrijednost AUCss bila je 2,35 ng.h/mL (28,0%) u kombinaciji s enkorafenibom na temelju populacijskog PK modeliranja.
English: • Muscle problems: Mektovi can cause breakdown of muscle (rhabdomyolysis).
Croatian: • Problemi s mišićima: lijek Mektovi može prouzročiti razgradnju mišića (rabdomiolizu).
English: Binimetinib is a weak inhibitor of OAT3, and caution should be taken when it is used with sensitive substrates (such as pravastatin or ciprofloxacin).
Croatian: Binimetinib je slab inhibitor prijenosnika OAT3 i potreban je oprez kada se koristi s osjetljivim supstratima (kao što su pravastatin ili ciprofloksacin).
English: Tell your doctor, pharmacist or nurse immediately if you get the following while you are taking this medicine:
Croatian: Odmah obavijestite svog liječnika, ljekarnika ili medicinsku sestru ako tijekom uzimanja ovog lijeka primijetite sljedeće:
English: Hypertensive adverse reactions required additional therapy in 8.0 % (22/274) of patients.
Croatian: Hipertenzije kao nuspojave zahtijevale su dodatno liječenje u 8,0% (22/274) bolesnika.
English: • lung or breathing problems
Croatian: • probleme s plućima ili disanjem
English: Benefits and risks should be carefully considered before administering binimetinib in combination with encorafenib to patients with a prior or concurrent cancer associated with RAS mutation.
Croatian: Potrebno je pomno razmotriti koristi i rizike prije primjene binimetiniba u kombinaciji s enkorafenibom bolesnicima s prijašnjom ili postojećom zloćudnom bolešću povezanom s RAS mutacijom.
English: In this patient, rhabdomyolysis was observed with concomitant symptomatic Grade 4 CK elevation.
Croatian: U tog bolesnika, rabdomioliza je primijećena uz prateće simptomatsko povišenje kreatin kinaze stupnja 4.
English: Binimetinib is to be given in combination with encorafenib.
Croatian: Binimetinib se daje u kombinaciji s enkorafenibom.
English: Patients should be assessed at each visit for symptoms of new or worsening visual disturbances.
Croatian: Pri svakoj kontroli se mora provesti procjenu novih simptoma ili pogoršanja poremećaja vida u bolesnika.
English: Interstitial lung disease (ILD)/pneumonitis • Grade 2
Croatian: Intersticijska bolest pluća (IBP)/pneumonitis • Stupanj 2
English: Binimetinib has minor influence on the ability to drive or use machines.
Croatian: Binimetinib malo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
English: How to take Mektovi
Croatian: Kako uzimati lijek Mektovi
English: The most common adverse reactions (>25%) occurring in patients treated with encorafenib 300 mg administered with binimetinib were fatigue, nausea and diarrhoea.
Croatian: Najčešće nuspojave (> 25%) u bolesnika liječenih enkorafenibom 300 mg u kombinaciji s binimetinibom bile su umor, mučnina i proljev.
English: Binimetinib inhibits growth of BRAF V600 mutant melanoma cell lines and demonstrates anti-tumour effects in BRAF V600 mutant melanoma animal models.
Croatian: Binimetinib inhibira rast staničnih linija melanoma s BRAF V600 mutacijom i pokazuje antitumorske učinke u životinjskim modelima melanoma s
English: The efficacy and safety of binimetinib in combination with encorafenib have been established only in patients with tumours expressing BRAF V600E and V600K mutations.
Croatian: Djelotvornost i sigurnost binimetiniba u kombinaciji s enkorafenibom ustanovljena je samo u bolesnika s tumorima koji izražavaju BRAF V600E i V600K mutacije.
English: If a dose of binimetinib is missed, it should not be taken if it is less than 6 hours until the next dose is due.
Croatian: Ako bolesnik propusti dozu binimetiniba, ne smije ju uzeti ako do sljedeće doze po rasporedu ima manje od 6 sati.